Pharus Diagnostics
PrivateLast Round
Early Funding
May 4, 2025
Est. Valuation
$30M
Total Funding Raised
$11M
Company Overview
Pharus Diagnostics is a biotechnology company that develops liquid biopsy tests for the early detection of cancer using proprietary RNA-based technology and machine learning.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pharus Diagnostics Comparables
Compare Pharus Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Amplified Sciences | 81% | |
| Mercy BioAnalytics | 77% | |
| Singlera Genomics Inc. | 77% |
Pharus Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 4, 2025 | ||||
| Series A Extension | Jul 25, 2022 | ||||
| VC Round | Jul 1, 2022 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2025
Completed an early funding round.
- May 2, 2025
Monthly visitors grew 176% MoM, reaching 2.1K.
Pharus Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access